Role of neoadjuvant therapy for nonmetastatic pancreatic cancer:Current evidence and future perspectives  

作　　者：Gianluca Cassese Ho-Seong Han Yoo-Seok Yoon Jun Suh Lee Boram Lee Antonio Cubisino Fabrizio Panaro Roberto Ivan Troisi 

机构地区：[1]Department of Clinical Medicine and Surgery,Division of Minimally Invasive HPB Surgery and Transplantation Service,Federico II University Hospital,Naples 80131,Italy [2]Department of Surgery,Seoul National University College of Medicine,Seongnam 13620,Gyeonggi-do,South Korea [3]Department of HPB Surgery and Transplantation,Beaujon Hospital,Clichy 92110,France [4]Department of Digestive Surgery and Liver Transplantation,CHU Montpellier,Montpellier 34100,France

出　　处：《World Journal of Gastrointestinal Oncology》2023年第6期911-924,共14页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：Pancreatic adenocarcinoma(PDAC)is one of the most common and lethal human cancers worldwide.Surgery followed by adjuvant chemotherapy offers the best chance of a long-term survival for patients with PDAC,although only approximately 20%of the patients have resectable tumors when diagnosed.Neoadjuvant chemotherapy(NACT)is recommended for borderline resectable pancreatic cancer.Several studies have investigated the role of NACT in treating resectable tumors based on the recent advances in PDAC biology,as NACT provides the potential benefit of selecting patients with favorable tumor biology and controls potential micro-metastases in high-risk patients with resectable PDAC.In such challenging cases,new potential tools,such as ct-DNA and molecular targeted therapy,are emerging as novel therapeutic options that may improve old paradigms.This review aims to summarize the current evidence regarding the role of NACT in treating non-metastatic pancreatic cancer while focusing on future perspectives in light of recent evidence.

关 键 词：Pancreatic cancer Pancreatic duct adenocarcinoma Neoadjuvant chemotherapy Borderline resectable Locally advanced pancreatic cancer 

分 类 号：R735.9[医药卫生—肿瘤]